Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CC-885 是一种 CRBN 蛋白调节剂,有抗肿瘤的潜能。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 315 | 现货 | ||
5 mg | ¥ 747 | 现货 | ||
10 mg | ¥ 1,080 | 现货 | ||
25 mg | ¥ 2,320 | 现货 | ||
50 mg | ¥ 3,490 | 现货 | ||
100 mg | ¥ 5,120 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 865 | 现货 |
产品描述 | CC-885 is a modulator of cereblon (CRBN). It has potent anti-tumour activity. |
体外活性 | The effect of CC-885 on cell proliferation in AML cell lines, THLE-2 and human PBMC is more powerful than Lenalidomide and Pomalidomide with IC50s>10 μM. CC-885 is tested in 293T HEK cells stably expressing the CC-885-sensitive or -resistant GSPT1 variants. Acute myeloblatlic leukemia (AML) cell lines, human liver epithelial cell line (THLE-2) and human peripheral blood mononuclear cells (PBMC) are treated with varying concentrations of CC-885, with IC50s of 10×-6-1 μM. To address whether the cereblon-dependent degradation of GSPT1 is responsible for the cytotoxic effects of CC-885, a GSPT1 mutant that retains its normal function, but loses CC-885-dependent cereblon binding, is used to distinguish the role of GSPT1 from that of other substrates. Overexpression of a resistant variant GSPT1Δ(1–138)/(G575N) completely abrogate the CC-885-induced anti-proliferation. Whereas overexpression of a CC-885-sensitive variant GSPT1Δ(1-138) only confer partial protection. Similar results are obtained in AML cell lines[1]. |
分子量 | 440.88 |
分子式 | C22H21ClN4O4 |
CAS No. | 1010100-07-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 67.5 mg/mL (153.10 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2682 mL | 11.341 mL | 22.6819 mL | 56.7048 mL |
5 mM | 0.4536 mL | 2.2682 mL | 4.5364 mL | 11.341 mL | |
10 mM | 0.2268 mL | 1.1341 mL | 2.2682 mL | 5.6705 mL | |
20 mM | 0.1134 mL | 0.567 mL | 1.1341 mL | 2.8352 mL | |
50 mM | 0.0454 mL | 0.2268 mL | 0.4536 mL | 1.1341 mL | |
100 mM | 0.0227 mL | 0.1134 mL | 0.2268 mL | 0.567 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CC-885 1010100-07-8 Others PROTAC Ligand for E3 Ligase Ligands for E3 Ligase CC 885 CC885 E3 ligase-recruiting Moiety Inhibitor inhibit inhibitor